Feed ABPO
Summary
68 / 100 · Bulios Score
Valuation 100Growth -Profitability -Quality 79Debt 53Stability 19
What speaks for it
- It earns 190 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $4.24M against $171.0K.
- You pay 1.2 USD for 1 USD of yearly profit, little for its sector.
What to watch
- It passes only 3 of the 9 points of the Piotroski financial health test.
- For every 100 USD of bills due within a year it has 62 USD of short-term assets.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapP/E today 1.2
Biotechnology industry median
Today you pay 1.2 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
20212022202320242025
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $4.24M
Debt $171.0K
Free cash flow over 12 months -$6.04M
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.